CN Patent

CN105232471A — 含有无定形cddo-me的延迟释放口服组合物

Assigned to Reata Pharmaceuticals Inc · Expires 2016-01-13 · 10y expired

What this patent protects

本发明的药物制剂含有与亲水性粘合剂混合的无定形bardoxolone甲基颗粒(纯的形式或固体分散体形式)，该药物制剂除了其他性质表现出理想的低Cmax。这种制剂具有与基于bardoxolone甲基的结晶形式的制剂相比较高的口服生物利用度的优势。

USPTO Abstract

本发明的药物制剂含有与亲水性粘合剂混合的无定形bardoxolone甲基颗粒(纯的形式或固体分散体形式)，该药物制剂除了其他性质表现出理想的低Cmax。这种制剂具有与基于bardoxolone甲基的结晶形式的制剂相比较高的口服生物利用度的优势。

Drugs covered by this patent

Patent Metadata

Patent number
CN105232471A
Jurisdiction
CN
Classification
—
Expires
2016-01-13
Drug substance claim
No
Drug product claim
No
Assignee
Reata Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.